Hoth Therapeutics, Inc. (HOTH) announced combined positive findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT, including compelling anti-tumor efficacy, and new GLP-validated bioanalytical results that exceeded internationally recognized regulatory thresholds. Hoth expects to integrate the bioanalytical data into its formal GLP toxicology package and is preparing for an IND.
Robb Knie, CEO of Hoth Therapeutics, said: "We believe HT-KIT has the potential to transform outcomes in KIT-driven cancers, and these milestones accelerate our path toward IND submission and first-in-human trials."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.